About Pancreatic lipase-related protein 3
Pancreatic lipase-related protein 3 (PNLIPRP3) is a protein
from Homo sapiens identified by UniProt accession
Q17RR3, 467 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Pancreatic lipase-related protein 3 |
| UniProt accession | Q17RR3 |
| Gene | PNLIPRP3 |
| Organism | Homo sapiens |
| Length | 467 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (16)
Diseases linked to this target (Open Targets).
- genetic disorder · score 0.12
- lung adenocarcinoma · score 0.11
- cutaneous melanoma · score 0.11
- esophageal cancer · score 0.10
- squamous cell lung carcinoma · score 0.10
- esophageal squamous cell carcinoma · score 0.04
- hepatocellular carcinoma · score 0.01
- dysplasia · score 0.01
- rosacea · score 0.01
- acne · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q17RR3-F1 | alphafold | PREDICTED | 89.27 | — |
Amino-acid sequence (467 residues)
MLGIWIVAFL FFGTSRGKEV CYERLGCFKD GLPWTRTFST ELVGLPWSPE KINTRFLLYT IHNPNAYQEI SAVNSSTIQA SYFGTDKITR INIAGWKTDG KWQRDMCNVL LQLEDINCIN LDWINGSREY IHAVNNLRVV GAEVAYFIDV LMKKFEYSPS KVHLIGHSLG AHLAGEAGSR IPGLGRITGL DPAGPFFHNT PKEVRLDPSD ANFVDVIHTN AARILFELGV GTIDACGHLD FYPNGGKHMP GCEDLITPLL KFNFNAYKKE MASFFDCNHA RSYQFYAESI LNPDAFIAYP CRSYTSFKAG NCFFCSKEGC PTMGHFADRF HFKNMKTNGS HYFLNTGSLS PFARWRHKLS VKLSGSEVTQ GTVFLRVGGA VRKTGEFAIV SGKLEPGMTY TKLIDADVNV GNITSVQFIW KKHLFEDSQN KLGAEMVINT SGKYGYKSTF CSQDIMGPNI LQNLKPC
Explore Pancreatic lipase-related protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets